Hing C. Wong
YOU?
Author Swipe
View article: Generation of HIV- and CD19-Specific TSCM CAR-T Cells by a Novel Cytokine-Based Scaffold 2319
Generation of HIV- and CD19-Specific TSCM CAR-T Cells by a Novel Cytokine-Based Scaffold 2319 Open
Description While activation of T-cells with anti-CD3/CD28 (aCD3/28) enables efficient lentiviral transduction to generate CAR-Ts, these CAR-Ts are more differentiated with reduced in vivo persistence. We hypothesized that T-cell treatment…
View article: A humanized IL-2 fusion protein enhances T regulatory cells in vivo and restrains disease in a murine model of Alopecia Areata 4760
A humanized IL-2 fusion protein enhances T regulatory cells in vivo and restrains disease in a murine model of Alopecia Areata 4760 Open
Description Alopecia Areata (AA) is a common autoimmune disease that presents as nonscarring hair loss. AA is associated with a collapse of immune privilege of the hair follicle, marked by increased MHC expression, immune cell infiltrates …
View article: Natural killer cell TGF-β signaling regulates senolytic activity and vascular patterning in the postnatal lung
Natural killer cell TGF-β signaling regulates senolytic activity and vascular patterning in the postnatal lung Open
Background Bronchopulmonary dysplasia (BPD) is a disease of neonatal lung development that is linked to impaired pulmonary vascularization, dysregulated transforming growth factor-β (TGF-β) signaling and the accumulation of senescent cells…
View article: Imaging findings of post-chemotherapy non-metastatic hepatic parenchymal changes
Imaging findings of post-chemotherapy non-metastatic hepatic parenchymal changes Open
The use of chemotherapy has revolutionized the management of cancer in the past decades. Liver toxicity is commonly observed among different types of chemotherapy drugs. The aim of this pictorial review is to illustrate radiological featur…
View article: Causal Relationship Between Blood Metabolites and Prostate Cancer Risk: A Two‐Sample Mendelian Randomization Study
Causal Relationship Between Blood Metabolites and Prostate Cancer Risk: A Two‐Sample Mendelian Randomization Study Open
Recent research has increasingly suggested an association between changes in specific blood metabolites and prostate cancer (PCa) development. However, it remains unclear whether these observed associations represent a causal relationship.…
View article: A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy
A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy Open
Adoptive cellular therapy (ACT) using memory-like (ML) natural killer (NK) cells, generated through overnight ex vivo activation with IL-12, IL-15, and IL-18, has shown promise for treating hematologic malignancies. We recently reported th…
View article: Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques Open
The eradication of the viral reservoir represents the major obstacle to the development of a clinical cure for established HIV-1 infection. Here, we demonstrate that the administration of N-803 (brand name Anktiva) and broadly neutralizing…
View article: 767 Pre-clinical and first-in-human studies of HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in advanced solid tumors
767 Pre-clinical and first-in-human studies of HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in advanced solid tumors Open
Background HCW9218 is a bifunctional protein complex comprising dimeric extracellular domains of human transforming growth factor beta (TGF-β) receptor II and interleukin-15 (IL-15). HCW9218 1) stimulates immune effector cells and 2) seque…
View article: 243 Efficient generation of CD8<sup>+</sup> T<sub>SCM</sub> CD19 chimeric antigen receptor T-cells (CAR-T cells) by treatment with novel cytokine-based scaffolds
243 Efficient generation of CD8<sup>+</sup> T<sub>SCM</sub> CD19 chimeric antigen receptor T-cells (CAR-T cells) by treatment with novel cytokine-based scaffolds Open
Background Despite the success of CAR-T therapy in treating relapsed/refractory B-cell malignancies, >40% of patients experience relapse in part due to reduction of CAR-T function and poor persistence. Traditional αCD3/αCD28-based activati…
View article: Supplementary Figures 1-8 and Tables 1-3 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Figures 1-8 and Tables 1-3 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Supplemental Figures 1-8, Supplemental Tables 1-3
View article: Supplementary Table 5 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Table 5 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Table 5 Excel Document
View article: Supplementary Table 4 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Table 4 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Table 4 Excel Document
View article: Supplementary Figure Legends from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Figure Legends from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Legends for Supplementary Figures 1-8 and Supplementary Tables 1-5
View article: Supplementary Table 5 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Table 5 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Table 5 Excel Document
View article: Data from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Data from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Natural killer (NK) cells are a promising cellular therapy for cancer, with challenges in the field including persistence, functional activity, and tumor recognition. Briefly, priming blood NK cells with recombinant human (rh)IL-12, rhIL-1…
View article: Supplementary Table 4 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Table 4 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Table 4 Excel Document
View article: Supplementary Figures 1-8 and Tables 1-3 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Figures 1-8 and Tables 1-3 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Supplemental Figures 1-8, Supplemental Tables 1-3
View article: Data from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Data from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Natural killer (NK) cells are a promising cellular therapy for cancer, with challenges in the field including persistence, functional activity, and tumor recognition. Briefly, priming blood NK cells with recombinant human (rh)IL-12, rhIL-1…
View article: Supplementary Figure Legends from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Supplementary Figure Legends from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy Open
Legends for Supplementary Figures 1-8 and Supplementary Tables 1-5
View article: Supplementary methods, Supplementary tables 1 through 4, and Supplementary figure 1 from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Supplementary methods, Supplementary tables 1 through 4, and Supplementary figure 1 from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models Open
Supplementary methods. Supplementary Table S1. Antibodies used in immune cell characterization by flow cytometry. Supplementary Table S2. PK parameters of ALT-803 administered to cynomolgus monkeys. Supplementary Table S3. Representative c…
View article: Data from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Data from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models Open
IL15, a potent stimulant of CD8+ T cells and natural killer (NK) cells, is a promising cancer immunotherapeutic. ALT-803 is a complex of an IL15 superagonist mutant and a dimeric IL15 receptor αSu/Fc fusion protein that was found to exhibi…
View article: Data from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Data from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models Open
IL15, a potent stimulant of CD8+ T cells and natural killer (NK) cells, is a promising cancer immunotherapeutic. ALT-803 is a complex of an IL15 superagonist mutant and a dimeric IL15 receptor αSu/Fc fusion protein that was found to exhibi…
View article: Supplementary methods, Supplementary tables 1 through 4, and Supplementary figure 1 from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Supplementary methods, Supplementary tables 1 through 4, and Supplementary figure 1 from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models Open
Supplementary methods. Supplementary Table S1. Antibodies used in immune cell characterization by flow cytometry. Supplementary Table S2. PK parameters of ALT-803 administered to cynomolgus monkeys. Supplementary Table S3. Representative c…
View article: Supplementary Table 1 from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas
Supplementary Table 1 from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas Open
Characteristics of primary iNHL patient samples used in this study.
View article: Data from Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Data from Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors Open
Purpose: IL15 induces the activation and proliferation of natural killer (NK) and memory CD8+ T cells and has preclinical antitumor activity. Given the superior activity and favorable kinetics of ALT-803 (IL15N72D:IL15RαSu/IgG1 Fc complex)…
View article: Data from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas
Data from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas Open
Purpose: Anti-CD20 monoclonal antibodies (mAb) are an important immunotherapy for B-cell lymphoma, and provide evidence that the immune system may be harnessed as an effective lymphoma treatment approach. ALT-803 is a superagonist IL-15 mu…
View article: Supplementary Figure 2 from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas
Supplementary Figure 2 from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas Open
Human NK cell engraftment and proliferation in NSG mice with ALT-803 administration.
View article: Supplementary Figure Legends from Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Supplementary Figure Legends from Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors Open
Supplementary Figure 1-3 Legends
View article: Supplementary Figure 1 from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas
Supplementary Figure 1 from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas Open
Spleen NK cell numbers and percentages in SCID mice analyzed in Figures 4E/F.